Abbvie Inc

NYSE: ABBV
$166.28
+$1.29 (+0.8%)
Closing Price on November 18, 2024

ABBV Articles

AbbVie released a better-than-expected second-quarter earnings report before the markets opened on Friday.
Despite the fact that energy has tumbled 20% from the highs posted in June, Jefferies remains bullish on the natural gas arena, and with good reason.
Bristol-Myers Squibb released a better-than-expected second-quarter earnings report before the markets opened on Thursday.
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
In a study that ranks “perceived strength” of companies rather than their financial performance, Apple Inc. (NASDAQ: AAPL) took the top spot. Research firm Future Brand described it selection...
24/7 Wall St. has put together a preview of Alphabet, Amazon.com, Facebook and some of the other major companies reporting their quarterly results this week.
With yields plunging and the market getting very pricey, some top pharmaceutical stocks are starting to look like a great total return vehicle for the rest of this year and into 2017.
The June 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest decreased.
The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity to buy into the markets and...
The short interest data have been released for the June 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through...
24/7 Wall St. has picked out the biggest movers and winners on Wednesday, particularly biopharma companies making serious runs in the session.
Though Infinity Pharmaceuticals announced that its DYNAMO study met its primary endpoint of overall response rate, the stock was still way down on the day for other reasons.
The Jefferies Healthcare Conference wrapped up in New York City last week, and the mood was reported as generally positive, with investors feeling much better than a few months ago.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Abbvie, Amazon.com, Cliffs Natural Resources, Corning, Dynegy, Joy Global and Stanley Black & Decker.